Frédéric Legros
Amministratore Delegato presso ARTHEx Biotech SL
Posizioni attive di Frédéric Legros
Società | Posizione | Inizio | Fine |
---|---|---|---|
ARTHEx Biotech SL
ARTHEx Biotech SL Miscellaneous Commercial ServicesCommercial Services ARTHEx Biotech S.L. engages in the development of antisense RNA (ribonucleic acid) treatments against genetic diseases. It offers Anti-microRNAs for the treatment of unmet genetic diseases. The company was founded by Beatriz Llamus? and Rub?n Artero on September 27, 2019 and is headquartered in Paterna, the United Kingdom. | Amministratore Delegato | 03/05/2023 | - |
Presidente | 28/11/2022 | - | |
Anoat Therapeutics SAS
Anoat Therapeutics SAS BiotechnologyHealth Technology Anoat Therapeutics SAS develops novel therapies for cystic fibrosis. The company is based in Paris, France. The French company was founded in 2023. Vincent Bischoff has been the CEO of the company since 2023. | Presidente | 25/03/2023 | - |
Storia della carriera di Frédéric Legros
Precedenti posizioni note di Frédéric Legros
Società | Posizione | Inizio | Fine |
---|---|---|---|
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Direttore operativo | 01/01/2017 | 01/10/2022 |
VALNEVA | Corporate Officer/Principal | - | 01/01/2017 |
Cnrs Innovation SA
Cnrs Innovation SA Miscellaneous Commercial ServicesCommercial Services CNRS Innovation SA is a French company that focuses on research and innovation. The company is based in Boulogne-Billancourt, France. The company has been in the industry for over 30 years and have a team of experts who provide services to clients. The company has signed numerous operating contracts since 2012 and has supported many start-ups since 2019. The company has subsidiaries and are ultimately controlled by the Centre National de la Recherche Scientifique. | Corporate Officer/Principal | 01/09/2003 | 01/10/2005 |
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Direttore/Membro del Consiglio | - | - |
Formazione di Frédéric Legros
NEOMA Business School | Undergraduate Degree |
Statistiche
Distribuzione geografica
Francia | 7 |
Spagna | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Chairman | 2 |
Chief Operating Officer | 1 |
Settori
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
VALNEVA | Health Technology |
Aziende private | 5 |
---|---|
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Health Technology |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
Cnrs Innovation SA
Cnrs Innovation SA Miscellaneous Commercial ServicesCommercial Services CNRS Innovation SA is a French company that focuses on research and innovation. The company is based in Boulogne-Billancourt, France. The company has been in the industry for over 30 years and have a team of experts who provide services to clients. The company has signed numerous operating contracts since 2012 and has supported many start-ups since 2019. The company has subsidiaries and are ultimately controlled by the Centre National de la Recherche Scientifique. | Commercial Services |
ARTHEx Biotech SL
ARTHEx Biotech SL Miscellaneous Commercial ServicesCommercial Services ARTHEx Biotech S.L. engages in the development of antisense RNA (ribonucleic acid) treatments against genetic diseases. It offers Anti-microRNAs for the treatment of unmet genetic diseases. The company was founded by Beatriz Llamus? and Rub?n Artero on September 27, 2019 and is headquartered in Paterna, the United Kingdom. | Commercial Services |
Anoat Therapeutics SAS
Anoat Therapeutics SAS BiotechnologyHealth Technology Anoat Therapeutics SAS develops novel therapies for cystic fibrosis. The company is based in Paris, France. The French company was founded in 2023. Vincent Bischoff has been the CEO of the company since 2023. | Health Technology |
- Borsa valori
- Insiders
- Frédéric Legros
- Esperienza